

# Rupert Mcshane

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/10553724/rupert-mcshane-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

3,215  
citations

26  
h-index

45  
g-index

45  
ext. papers

3,798  
ext. citations

7.1  
avg, IF

4.72  
L-index

#	Paper	IF	Citations
43	Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 893-903	59.2	483
42	The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. <i>Lancet Neurology</i> , <b>2009</b> , 8, 151-7	24.1	434
41	Lack of evidence for the efficacy of memantine in mild Alzheimer disease. <i>Archives of Neurology</i> , <b>2011</b> , 68, 991-8		182
40	Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. <i>BMJ: British Medical Journal</i> , <b>1997</b> , 314, 266-70		164
39	Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. <i>American Journal of Geriatric Psychiatry</i> , <b>2020</b> , 28, 121-141	6.5	155
38	Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. <i>Neurology</i> , <b>2014</b> , 83, 364-73	6.5	146
37	Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. <i>British Journal of Psychiatry</i> , <b>1999</b> , 174, 39-44	5.4	146
36	A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). <i>PLoS Medicine</i> , <b>2008</b> , 5, e76	11.6	144
35	Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 536-44	4.6	124
34	Getting lost in dementia: a longitudinal study of a behavioral symptom. <i>International Psychogeriatrics</i> , <b>1998</b> , 10, 253-60	3.4	113
33	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , <b>2015</b> , 14, 1171-81	24.1	101
32	A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 114-9	4.6	100
31	Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 419-426	23.3	92
30	Behaviour changes in dementia. 2: Are there behavioural syndromes?. <i>International Journal of Geriatric Psychiatry</i> , <b>1997</b> , 12, 1074-8	3.9	84
29	Ketamine and other glutamate receptor modulators for depression in adults. <i>The Cochrane Library</i> , <b>2015</b> , CD011612	5.2	79
28	Memantine for dementia. <i>The Cochrane Library</i> , <b>2019</b> , 3, CD003154	5.2	79
27	Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , <b>2014</b> , CD008782	5.2	67

26	Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies. <i>The Cochrane Library</i> , <b>2013</b> ,	5.2	61
25	Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. <i>BMJ Open</i> , <b>2012</b> , 2,	3	59
24	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, e96-e105	1.2	57
23	The feasibility of electronic tracking devices in dementia: a telephone survey and case series. <i>International Journal of Geriatric Psychiatry</i> , <b>1998</b> , 13, 556-63	3.9	51
22	Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. <i>The Cochrane Library</i> , <b>2015</b> , CD011611	5.2	48
21	Electronic Tracking for People with Dementia Who Get Lost outside the Home: A Study of the Experience of Familial Carers. <i>British Journal of Occupational Therapy</i> , <b>2010</b> , 73, 152-159	1	45
20	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. <i>Trials</i> , <b>2009</b> , 10, 57	2.8	36
19	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). <i>International Journal of Geriatric Psychiatry</i> , <b>2017</b> , 32, 1205-1216	3.9	32
18	What Are the Syndromes of Behavioral and Psychological Symptoms of Dementia?. <i>International Psychogeriatrics</i> , <b>2000</b> , 12, 147-153	3.4	28
17	Assessment of need and practice for assistive technology and telecare for people with dementia-The ATTILA (Assistive Technology and Telecare to maintain Independent Living At home for people with dementia) trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 420-430	6	14
16	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , <b>2020</b> , 266, 615-620.6		12
15	Medical cannabis in the UK: From principle to practice. <i>Journal of Psychopharmacology</i> , <b>2020</b> , 34, 931-937.6		11
14	Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic. <i>BMJ Open</i> , <b>2019</b> , 9, e029108	3	10
13	Are methodological quality and completeness of reporting associated with citation-based measures of publication impact? A secondary analysis of a systematic review of dementia biomarker studies. <i>BMJ Open</i> , <b>2018</b> , 8, e020331	3	10
12	Characteristics of patients expressing an interest in ketamine treatment: results of an online survey. <i>BJPsych Open</i> , <b>2018</b> , 4, 389-392	5	6
11	Exploring patients' and carers' views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study. <i>BJPsych Open</i> , <b>2019</b> , 5, e62	5	5
10	Should patients with dementia who wander be electronically tagged? Yes. <i>BMJ, The</i> , <b>2013</b> , 346, f3603	5.9	5
9	Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. <i>The Cochrane Library</i> , <b>2021</b> , 10, CD011611	5.2	5

8	GPS tracking for people with dementia. <i>Working With Older People</i> , <b>2009</b> , 13, 34-37	0.6	4
7	Training and assessing independent nurse prescribers: a model for old age psychiatry. <i>Psychiatric Bulletin</i> , <b>2009</b> , 33, 350-353		2
6	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. <i>The Cochrane Library</i> , <b>2021</b> , 9, CD011612	5.2	2
5	Assessment and Management of Behavioural and Psychological Symptoms of Dementia (BPSD)241-244		1
4	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within a general practice (primary care) setting. <i>The Cochrane Library</i> , <b>2021</b> , 7, CD010771	5.2	1
3	Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences. <i>BJPsych Open</i> , <b>2020</b> , 7, e9	5	0
2	Ketamine for Psychiatric Disorders <b>2019</b> , 149-160		
1	F5-01-03: RESEARCH EVIDENCE ABOUT DIAGNOSIS, PREVENTION, AND PHARMACEUTICAL INTERVENTIONS FOR ALZHEIMER DISEASE IS OVERSOLD <b>2014</b> , 10, P282-P282		